MedTrace Logo

Hepatitis B Virus Vertical Transmission From HIV-HBV Co-infected Women

NCT02044068 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 35

Last updated 2017-04-28

No results posted yet for this study

Summary

Vertical HIV transmission has been dramatically reduced by the use of combined antiretroviral therapy in HIV-infected pregnant women. Among the most often used drugs, several have dual activity, against HIV and HBV: lamivudine, emtricitabine, tenofovir. Studies about vertical HBV transmission from HIV-HBV co-infected pregnant women are rare in developed countries. The study hypothesis is a major reduction of the risk of HBV vertical transmission.

Conditions

  • Vertical Disease Transmission
  • HBV

Sponsors & Collaborators

  • Hopital Lariboisière

    lead OTHER

Principal Investigators

  • Pierre O SELLIER, MD, PhD · Hopital Lariboisiere, Paris, France

Eligibility

Min Age
9 Months
Max Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2015-09-30
Completion
2015-09-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02044068 on ClinicalTrials.gov